Exhibit 99.1 20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress Full Year 2025 Revenue of $2.0 Million, up 17% from 2024 Gross Profit Increased 68% in FY 2025 and Gross Margin Expanded 900 bps State-Funded Firefighter Cancer Screening Program Expected to Drive Significant Revenue Growth in Q2 and Full Year 2026 Recent Nasdaq Listing Under Ticker Symbol "AIDX" and New Growth Initiatives Position 20/20 BioLabs for 2026 Expansion Gaithersburg, MD — March 31, 2026 — 20/20 Bio ...